Astellas Pharma ADR (ALPMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 03-2020 | 03-2019 | 03-2018 | 03-2017 | 03-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,251,000 | 2,243,000 | 2,058,000 | 2,516,000 | 2,172,691 |
| Depreciation Amortization | 609,000 | 572,000 | 612,000 | 570,000 | 574,260 |
| Accounts receivable | -150,000 | -231,000 | -63,000 | 45,000 | -129,887 |
| Accounts payable and accrued liabilities | -196,000 | 368,000 | -413,000 | 140,000 | -268,845 |
| Other Working Capital | -841,000 | -542,000 | -732,000 | -53,000 | -1,247,698 |
| Other Operating Activity | 364,000 | -80,000 | 1,487,000 | -1,114,000 | 1,503,496 |
| Operating Cash Flow | $2,037,000 | $2,330,000 | $2,949,000 | $2,104,000 | $2,604,017 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -315,000 | -38,000 | -226,000 | -248,000 | -263,600 |
| Net Acquisitions | -2,943,000 | -174,000 | -790,000 | -455,000 | -354,020 |
| Purchase Of Investment | N/A | N/A | -7,000 | 252,000 | -6,217 |
| Sale Of Investment | N/A | N/A | 66,000 | N/A | 139,000 |
| Purchase Sale Intangibles | -336,000 | -243,000 | -143,000 | -175,000 | -702,222 |
| Other Investing Activity | -318,000 | -164,000 | -192,000 | -204,000 | -735,679 |
| Investing Cash Flow | $-3,576,000 | $-376,000 | $-1,149,000 | $-655,000 | $-1,220,515 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 2,991,000 | N/A | N/A | N/A | N/A |
| Common Stock Repurchased | -485,000 | -1,445,000 | -1,233,000 | -823,000 | -997,054 |
| Dividend Paid | -675,000 | -649,000 | -676,000 | -626,000 | -577,805 |
| Other Financing Activity | -170,000 | -11,000 | -10,000 | -35,000 | -31,008 |
| Financing Cash Flow | $1,661,000 | $-2,105,000 | $-1,919,000 | $-1,484,000 | $-1,605,867 |
| Exchange Rate Effect | -55,000 | -19,000 | 32,000 | -136,000 | -79,755 |
| Beginning Cash Position | 2,854,000 | 2,989,000 | 3,216,000 | 3,215,000 | 3,290,369 |
| End Cash Position | 2,921,000 | 2,802,000 | 3,130,000 | 3,044,000 | 2,988,249 |
| Net Cash Flow | $67,000 | $-187,000 | $-87,000 | $-171,000 | $-302,128 |
| Free Cash Flow | |||||
| Operating Cash Flow | 2,037,000 | 2,330,000 | 2,949,000 | 2,104,000 | 2,604,017 |
| Capital Expenditure | -379,000 | -227,000 | -237,000 | -259,000 | -278,150 |
| Free Cash Flow | 1,658,000 | 2,103,000 | 2,712,000 | 1,845,000 | 2,325,867 |